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Introduction
The crowded conditions that exist in many of this
nation's jails and prisons create an ideal environ-
ment for the transmission of infectious diseases.
Congregate living environments, insufficient
availability of soap, water, and clean laundry, and
barriers to prompt access to health care increase
the probability that microorganisms will be trans-
mitted from one person to another. Furthermore,
inmates are frequently moved from one location
to another with little, if any, advance notice, com-
plicating the diagnosis of infection, recognition of
an outbreak, interruption of transmission, and
control of disease.
Further complicating the appropriate manage-
ment of contagious illnesses in the correctional
setting is the high prevalence of comorbidities
such as mental illness and ongoing substance
abuse.  Many inmates are distrustful of authority
and reluctant to cooperate with health care
providers.  In addition, some jails and prisons
have been slow to ask for assistance from out-
side agencies when faced with outbreak situa-
tions, and published guidelines for the diagnosis
and treatment of communicable diseases are not
always readily applicable to the correctional set-
ting.
Over the past several years, infections due to
methicillin-resistant Staphylococcus aureus
(MRSA) have been increasingly recognized as a
major problem in many jails and prisons.  This
article will review the epidemiology of S. aureus
(SA) and MRSA infections, provide recommenda-
tions for MRSA diagnosis and treatment, discuss
education and prevention measures, and pro-
pose new correctional-specific standard and
transmission based (contact) precautions for
MRSA. 
Bacteriology and Epidemiology 
SA is a bacterium commonly found colonizing the
skin or in the anterior nares of healthy individuals.
Up to 50% of those in the general population are
colonized with SA, and asymptomatic coloniza-
tion is much more common than symptomatic
infection and disease.1 The prevalence of SA col-
onization is increased among injection drug
users, health care workers (HCWs), diabetics,
the incarcerated, and those who have chronic
skin conditions or indwelling urinary or vascular
catheters.1,2,3 In addition to the anterior nares,
common colonization sites include the axillae,
perineum, rectum, and pharynx. Although SA
often colonizes humans without causing disease,
it can be responsible for both minor skin infec-
tions and life threatening infections of the skin,
bone, joints, blood, heart valves, and lungs. SA is
easily spread from person to person by contact
with the skin of someone who is infected or colo-
nized with the bacteria. 
Until World War II, SA was almost universally sus-
ceptible to penicillin.  Within a few years of the
first clinical use of penicillin in the 1940s, peni-
cillin resistance was identified, predominantly in
the hospital setting. Penicillin resistance in SA is
often due to the production of beta lactamases,
enzymes that break down penicillin's beta lactam
ring and render the drug inactive. To date, over
200 penicillinases have been identified. Another
common resistance mechanism is the production
of altered penicillin binding proteins.  
In an effort to combat penicillin resistance among
SA, semi-synthetic penicillins that were less sus-
ceptible to bacterial penicillinases were devel-
oped.  The first such agent was methicillin, and
for this reason SA that is resistant to semi-syn-
thetic penicillins is referred to as MRSA.  Within a
year of the introduction of the beta-lactamase sta-
ble penicillin methicillin in 1960, MRSA strains
were identified. By the 1970s, MRSA was
increasingly recognized as an important
pathogen in hospitals, nursing homes, and other
long term care facilities in the United States.
Currently, more than half of all health care asso-
ciated SA infections in hospitals in this country
are due to MRSA (HA MRSA).4,5
The prevalence of MRSA colonization is less than
that of SA, but is rising.  MRSA colonization can
be transient or persist for many years.6 Risk fac-
If you have any problems with this fax transmission please call 800.748.4336 or e-mail us at IDCR@corrections.net
ABOUT IDCR
IDCR, a forum for correctional problem 
solving, targets correctional physicians, 
nurses, administrators, outreach workers,
and case managers. Published monthly and
distributed by email and fax, IDCR provides
up-to-the moment  information on HIV/AIDS,
hepatitis, and other infectious diseases, 
as well as efficient ways to administer 
treatment in the correctional environment.
Continuing Medical Education credits are
provided by Medical Education Collaborative
(MEC). This activity is jointly sponsored by
IDCR and  Medical Education Collaborative
(MEC). IDCR is distributed to all members of
the Society of Correctional Physicians (SCP) 
within the SCP publication, CorrDocs
(www.corrdocs.org).
EXECUTIVE EDITOR
Anne S. De Groot, MD
Associate Professor of Medicine (Adjunct)
Brown Medical School
CHIEF EDITOR
David A. Wohl, MD
Associate Professor of Medicine
University of North Carolina
AIDS Clinical Research Unit
DEPUTY EDITORS
Joseph Bick, MD
Chief Medical Officer,
California Medical Facility, California
Department of Corrections
Renee Ridzon, MD
Consultant
SUPPORTERS
IDCR is grateful for 
the support of the following 
companies through unrestricted 
educational grants:
Major Support: Abbott Laboratories and
Roche Pharmaceuticals. 
Sustaining: Gilead Sciences, Inc.,
GlaxoSmithKline, Schering-Plough Corp.,
Tibotec Therapeutics
WHAT’S INSIDE
Editor’s Letter pg 2
Spotlight pg 7
S.P. 101 pg 9
Save The Dates pg 11
News & Reviews pg 11
Self-Assessment Test pg 12
Course Evaluation pg 13
March 2007  Vol. 9, Issue 14
FORMERLY HEPP Report
Continued on page 3
J O I N T LY S P O N S O R E D  B Y M E D I C A L E D U C A T I O N  C O L L A B O R A T I V E ,  I N C .
IDCR and AAHIVM have united to improve
the quality of health care delivery in the
nation's correctional facilities by leveraging
the knowledge, experience and resources of
two diverse and accomplished groups of HIV
and correctional health care experts. 
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN THE
CORRECTIONAL SETTING
2Subscribe to IDCR
Fax to 401-272-7562 for any of the following: (please print clearly or type)
____  I would like to edit my existing contact information
____  I am a new IDCR subscriber and would like add my contact information
CHECK ONE: How would you like to receive IDCR?
___ Email: __________________    
___ Fax: ____________________
NAME: FACILITY:
STATE:
CIRCLE ALL THAT APPLY:
Physician Physician Assistant Nurse/Nurse Practitioner Nurse Administrator
Pharmacist          Medical Director/Administrator HIV Case Worker/Counselor        Other
Faculty Disclosure
*Disclosures are listed at the beginning of the articles.
The employees of Medical Education Collaborative have no
financial relationships to disclose. In accordance with the
Accreditation Council for Continuing Medical Education
Standards for Commercial Support, the faculty for this activity
have been asked to complete Conflict of Interest Disclosure
forms. Disclosures are listed at the end of articles.
Associate Editors
Rick Altice, MD
Yale University AIDS Program
David Paar, MD
Associate Professor of Medicine
University of Texas, Medical Branch
Dean Rieger, MD
Officer/Corporate Medical Director
Correct Care Solution
Karl Brown, MD, FACP
Infectious Disease Supervisor
PHS-Rikers Island
Ralf Jürgens
Consultant
Joseph Paris, PhD, MD, FSCP, CCHP
Former Medical Director
Georgia Dept. of Corrections
Lester Wright, MD, MPH
Chief Medical Officer
New York State Dept. of Correctional Services
Bethany Weaver, DO, MPH
Infectious Disease Consultant
Armor Correctional Health Services
David Thomas, MD, JD
Professor and Chairman,
Division of Correctional Medicine
NSU-COM
Editorial Board
Neil Fisher, MD
Medical Director, Chief Health Officer
Martin Correctional Institute
Lynn Taylor, MD
Assistant Professor of Medicine 
Brown University School of Medicine 
The Miriam Hospital
Michael Poshkus, MD
Associate Clinical Professor 
Brown University School of Medicine
Medical Program Director
Rhode Island Department of Corrections
Louis Tripoli, MD, FACFE
Vice President of Medical Affairs
Correctional Medical Services
Josiah Rich, MD
Associate Professor of Medicine and 
Community Health
Brown University School of Medicine
Steven F. Scheibel, MD
Medical Director 
Community Oriented Correctional Health Serviices
Mary Sylla
Director of Policy and Advocacy 
Center for Health Justice
Barry Zack, MPH
Executive Director
Centerforce
Eric Avery, MD
Associate Clinical Professor of Psychiatry
University of Texas, Medical Branch
Zelalem Temesgen, MD, AAHIVS
Associate Professor of Medicine 
Mayo Clinic College of Medicine
Director, HIV Clinic Disease Consultant
Division of Infectious Disease Mayo Clinic
Jim Montalto
The Corrections Connection
Layout
Jose Colon
The Corrections Connection
Distribution
Screened Images Multimedia
Managing Editor
Elizabeth Closson
IDCR
Dear Corrections Colleagues,
Several months ago I was sent an email from a correctional nurse overwhelmed by the number
of patients he was caring for with infections caused by methicillin resistant Staphylococcus aureus
(MRSA).  He was desperate for any information he could use to help him treat and contain his
facility's outbreak.  This issue is our answer to this plea for comprehensive guidance on the man-
agement of this increasingly troublesome infection.
The lead article by Dr. Joseph Bick of the California Department of Corrections is a one-stop
resource packed with practical information regarding the containment of MRSA that every correc-
tional clinician should read.  In addition, Dr. Bick provides a straightforward review of the proper
precautions for prevention of the spread of communicable diseases in a Standard Contact
Precautions 101.  Dr. Bick writes from experience and those who chose not to follow his lead do
so at their own risk. 
This month's Spotlight by Todd Correll, PharmD complements Dr. Bick's article by reviewing the
slew of recently approved antibiotics for Gram positive infections.  Dr. Correll provides a useful
overview of the indications, strengths and weaknesses of each of these important agents that you
will want to keep handy.
Creating issues of IDCR that you will want to keep handy is what we strive for.  A few years ago,
this periodical changed its name and focus from viral hepatitis and HIV to embrace other infec-
tions commonly encountered among incarcerated individuals.  We recognized that correctional
providers, such as the nurse who emailed me, desired a source of information regarding infec-
tious diseases that was not only reliable and unbiased but also relevant to the care of the incar-
cerated.  Since then, we have endeavored to provide our colleagues with material they would find
useful, if not indispensable.  To that nurse up to his ears in MRSA, this issue is for you.
Sincerely, 
David A. Wohl, MD
Associate Professor of Medicine
Division of Infectious Diseases
AIDS Clinical Research Unit 
The University of North Carolina - Chapel Hill
LETTER FROM THE EDITOR
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tors for colonization with MRSA include those
associated with SA colonization, as well as
current or recent hospitalization, residence in
a long-term care facility (nursing home,
skilled nursing facility, hospice), end stage
renal disease (ESRD), dialysis, surgery, a
prior history of MRSA disease or coloniza-
tion, recent or frequent antibiotic therapy,
recurrent skin disease, close contact with a
person who is infected or colonized with
MRSA, overcrowded living conditions such
as those encountered in military service and
correctional settings, skin or soft tissue infec-
tions that respond poorly to beta lactam
antibiotics, and participation in athletic activi-
ties that involve abrasions, skin to skin con-
tact, and/or sharing of equipment. Although
MRSA colonization increases the risk for
infection, most of those who are colonized
with MRSA do not develop infection and
many of those who do develop infection were
not previously colonized.
Initially, MRSA infections were predominantly
found among residents of hospitals, nursing
homes, and other health care facilities and
most community-acquired SA infections were
not MRSA.  Over the past two decades, com-
munity-acquired MRSA (CA MRSA) have
become increasingly common causes of skin
and soft tissue infections (SSTI) outside of
the health care setting. Outbreaks have been
described in the military, in jails and prisons,
in day care settings, among MSM, and in
those participating in athletic events.7,8,9,10,
11,12,13
Risk factors identified in jail and prison
MRSA outbreaks have included prolonged
incarceration, the presence of skin lacera-
tions and abrasions, previous antibiotic use,
inadequate skin hygiene, draining one's own
abscesses or performing one's own wound
dressing changes, washing one's own cloth-
ing by hand, sharing razors, clothing, linen,
or soap, restricted access to medical care,
and requiring co-payments to see a clini-
cian.11,12,13
New risk factors for MRSA infection continue
to be identified.  In one recent report, sexual
contact with an infected partner was found to
be the likely etiology of MRSA transmission
in three households in Manhattan.14 Most
recently, an increasing number of communi-
ty-acquired SSTIs due to MRSA have been
seen in persons with no identifiable risk fac-
tors. In one recent study of 280 consecutive
patients who were hospitalized with SA infec-
tion, clinical and epidemiologic risk factors
did not reliably distinguish between MRSA
and methicillin-sensitive SA (MSSA).15
There is ample evidence documenting the
role of HCWs in the spread of MRSA from
patient to patient and from HCWs to their
families. MRSA has been cultured from com-
puter keyboards used by clinicians in hospi-
tals, stethoscopes, blood pressure cuffs, oto-
scopes, and pagers.16,17,18,19,20,21,22 Some
HCWs erroneously believe that they do not
need to adhere to contact precautions when
they enter the rooms of MRSA-infected
patients as long as they avoid contact with
the MRSA infected person. However, MRSA
can be readily cultured from the gloves and
the gowns or uniforms of HCWs who have
been in the room of MRSA infected patients,
regardless of whether they were involved in
direct patient care or were performing other
non-patient care activities.23 Clinicians who
examine MRSA infected patients while wear-
ing gloves but not gowns frequently acquire
MRSA on their clothing and later transfer
MRSA to their hands.24 In addition, MRSA
can be cultured from environmental surfaces
in most hospital rooms housing MRSA infect-
ed or colonized patients. SA can survive for
months on environmental surfaces, creating
a potential reservoir for later transmis-
sion.24,25
HA MRSA has historically been distinguished
from CA MRSA based upon antibiotic sus-
ceptibility profiles, genetic features, and the
presence or absence of toxins such as bac-
teriocin, enterotoxins, and the Panton-
Valentine leukocidin. Over time, some of
these distinctions between CA and HA
MRSA have begun to fade, and some CA
MRSA now have susceptibility profiles that
are more similar to those traditionally found
in HA MRSA.   
Often, microorganisms that develop resis-
tance pay a competitive price and are less
virulent.  However, HA MRSA appears to be
even more virulent than MSSA, leading to
longer hospitalizations, higher mortality, and
increased costs.26,27,28 Contrary to the
experience with HA MRSA, the outcomes
among patients who have required admis-
sion to the hospital with CA MRSA have been
found to be quite similar to those with CA
MSSA.29
In both the correctional setting and the free
community, SSTIs have often been mistak-
enly attributed to spider bites. This may be
due to the sudden appearance of painful
lesions, and the common finding of arach-
nids in correctional settings. In reality, spi-
ders infrequently bite people and most spider
bites are benign. The misinterpretation of
MRSA skin lesions as spider bites has led to
delays in appropriate treatment and misguid-
ed vector control measures.  HCWs in the
correctional setting should be advised to
consider "spider bites" as infections due to
MRSA until proven otherwise.
Treatment
The first step in adequately treating infec-
tions due to MRSA is to ensure rapid access
to health care for all inmates who have
SSTIs. Access to medical care can be
improved by eliminating co-payment require-
ment for contagious conditions, employing
an adequate number of clinical staff, and
maintaining a 24/7 clinical operation for
urgent medical conditions. One intervention
that may be particularly useful in high risk
correctional settings is the establishment of
wound evaluation and treatment clinics.
Utilizing specially trained dedicated health
care teams to provide active surveillance for
SSTI, promptly initiate treatment, and attend
to wound dressings may lead to more rapid
diagnosis, treatment, and resolution of skin
lesions and less opportunity for transmission
to others.
When evaluating SSTIs and other infections
in which SA is common, clinicians must
maintain a high degree of suspicion for
MRSA. When possible, all significant SSTIs
should be cultured. Cultures are especially
valuable for establishing the local epidemiol-
ogy and resistance pattern for SSTI. Once
MRSA is identified within a facility as an
endemic organism causing SSTI, empiric
antibiotic selection should include an agent
that has activity against this organism.  The
ongoing collection of cultures helps guide
infection control decisions and assists in
definitive antibiotic selection for infections
that are rapidly progressing, severe and/or
life threatening, or poorly responsive to
empiric therapy.  Cultures can be collected
by either swabbing purulent material
obtained at the time of incision and drainage
or by aspiration of lesions with a syringe.
Surface swabs of open lesions are generally
less useful as they often reflect colonization
rather than causative infection.
In many cases, incision and drainage of the
accumulated purulent material is all that is
needed to resolve minor MRSA SSTI infec-
tions, and antibiotics are unnecessary. With
early lesions that have not yet suppurated,
moist heat can be applied with a hot wash-
cloth to promote drainage.  Antibiotics should
be utilized when sepsis, large facial lesions,
periorbital lesions, and/or significant cellulitis
are present. Antibiotics should also be
strongly considered as part of the treatment
for patients who have SSTIs in the setting of
immune compromise due to neutropenia,
ESRD, diabetes, or HIV infection. Table 1
provides detailed information regarding
antimicrobial agents useful in the treatment
of MRSA. 
The indiscriminate use of antibiotics can lead
to increased drug resistance and should be
discouraged.  MRSA are resistant to all beta
lactam antibiotics, including: penicillin, the
semi-synthetic penicillins methicillin, nafcillin,
oxacillin, dicloxacillin, and cloxacillin, all
cephalosporins (including cephalexin,
cephalothin, ceftriaxone, cefuroxime, cef-
tazidime, and cefazolin), and penicillins that
are co-formulated with clavulinic acid or sul-
bactam (for example augmentin, timentin,
unasyn). In addition, MRSA strains often
carry plasmids that lead to resistance to
other non-beta lactam antibiotics, such as
aminoglycosides, fluoroquinolones,
macrolides, and chloramphenicol. Many
MRSA strains are susceptible to trimetho-
prim-sulfamethoxazole, clindamycin, the
longer acting tetracyclines minocycline or
doxycycline, and rifampin.  Rifampin should
never be used as a single agent for the treat-
ment of MRSA, as resistance will rapidly
evolve.30,31
Clinicians should bear in mind that skin
lesions are commonly caused by bacteria
other than SA. Group A streptococci (GAS)
can cause impetigo and erysipelas, and are
commonly resistant to antibiotics that may be
used for MRSA such as trimethoprim-sul-
famethoxazole and the tetracyclines. If GAS
is suspected, it may be prudent to include a
second agent with activity against GAS in the
initial empiric therapy. Alternatively, clin-
damycin has the added benefit of being
effective against most MRSA as well as
GAS, and also has excellent bone penetra-
tion. 
3
METHICILLIN-RESISTANT STAPHYLOCOCCUS...
(continued from page 1)
March 2007      Vol. 9, Issue 14 visit IDCR online at www.IDCRonline.org
Continued on page 4
4
METHICILLIN-RESISTANT STAPHYLOCOCCUS...
(continued from page 3)
It is important to note that most MRSA resis-
tant to erythromycin have inducible resis-
tance to clindamycin.  This resistance may
not be recognized and reported to the clini-
cian unless the laboratory performs addition-
al testing.  This test, referred to as a d-zone
test or d-test, should be routinely performed
upon all SA isolates that are found to be
resistant to erythromycin.  Unless a d-zone
test has demonstrated susceptibility to clin-
damycin, this agent should not be used for
SA that is erythromycin resistant. For more
serious infections, vancomycin, linezolid,
daptomycin, tigacycline or quinupristin-dalfo-
pristin may be used (Table 1 and Spotlight). 
Vancomycin has been used for many years
for the treatment of SA and MRSA, and virtu-
ally all SA are fully susceptible to van-
comycin. However, occasional clinical iso-
lates of SA with reduced susceptibility to van-
comycin have been reported for over a
decade.30,31,32,33 The first documented case
of infection caused by vancomycin-resistant
S. aureus (VRSA) (vancomycin MIC >32
µg/mL) in a patient in the United States was
reported in 2002.34,35 Other concerns about
vancomycin include hypersensitivity reac-
tions, a histamine release syndrome (also
known as red man syndrome) related to
rapid intravenous infusion, the lack of an oral
formulation that can be used for the treat-
ment of systemic infection, and the possibili-
ty of vancomycin use contributing to the
development of vancomycin resistant entero-
coccus (VRE).  
Preventive and Infection Control
Strategies
In 2003, the Society for Health Care
Epidemiology of America (SHEA) released
guidelines for preventing the nosocomial
transmission of MRSA within hospitals.36
These guidelines included three main points:
1. Actively screening all at-risk patients at the
time of admission for infection or colonization
with MRSA. 
2. Use of contact precautions for all those
found to be colonized or infected with
MRSA .
3. Limitations on antibiotic use to decrease
the likelihood of antibiotic resistance.
These guidelines represent a significantly
more aggressive approach to the detection
of antibiotic resistant bacteria than has been
utilized in the past, and not all infection con-
trol practitioners have embraced these new
recommendations. The Health Care Infection
Control Practices Advisory Committee (HIC-
PAC) of the Centers for Disease Control and
Prevention (CDC) has proposed an alternate
approach, recommending that hospitals only
implement active surveillance if other mea-
sures fail to control the transmission of resis-
tant bacteria.  
Most recently, state governments have
waded into the debate.  At least two states
(Illinois and Maryland) have proposed legis-
lation that would mandate active screening of
all hospitalized patients for MRSA. SHEA
and the Association of Practitioners in
Infection Control (APIC) have come out in
opposition to legislative mandates for active
surveillance.37 It should be noted that there
are limited data to support these intensified
screening and isolation strategies. In the
United States the most compelling data for
routine surveillance come from experiences
in the control of hospital outbreaks and high
risk settings such as intensive care units and
hemodialysis units. Proponents of more
widespread screening in the hospital setting
often cite the experience in Denmark and
Holland.  These countries have maintained a
very aggressive practice of isolating all newly
admitted patients, screening them for MRSA,
and attempting environmental eradication
measures.  In some hospitals in Denmark
and Holland, MRSA represents only a few
percent of all SA isolated.  It is significant,
however, that the prevalence of MRSA in the
community in these countries is significantly
lower than that seen in most parts of the
United States. The high prevalence of CA
MRSA in this country may overwhelm efforts
to actively screen and isolate all those admit-
ted to hospitals. 
Health care and correctional facilities consid-
ering a more intensive approach to screening
for MRSA and isolation must consider a num-
ber of potential negative consequences.  The
workload involved in collecting and process-
ing specimens is formidable. Facilities must
have a physical plant that will allow for single
cell contact isolation or cohorting of those
who are found to be infected or colonized.
Tracking all involved patients and cultures
will require a functioning information technol-
ogy system, and the financial costs associat-
ed with routine culturing could be significant.
Studies have demonstrated that hospitalized
patients who are placed in isolation experi-
ence twice as many adverse events, are less
likely to have vital signs performed, have
more days without a doctor's progress note,
have longer lengths of stay, and are more
likely to file a formal complaint as compared
to those who are not isolated.(38)
Evidence-based experience with MRSA con-
trol measures in the correctional setting is
quite limited. Suggested interventions
include wide spread screening for skin dis-
ease, implementation of standardized antimi-
crobial treatment recommendations,
improvements in laundry practices, inmate
education, the use of chlorhexidine contain-
ing soaps, and the use of alcohol-based
hand rubs.  In 2003, the Federal Bureau of
Prisons issued recommendations that
include reporting and tracking of patients with
MRSA, draining abscesses, culturing skin
lesions, and selecting antibiotics known to be
effective against MRSA.39 Clearly, more
research is needed to define best practices
within jails and prisons for MRSA prevention,
diagnosis, and treatment. 
Can MRSA be Eradicated?
In general, routine eradication of MRSA colo-
nization has not been shown to be practical
or efficacious. In some cases in which the
same person develops repeated episodes of
infection, clearance of the organism from the
nose can be beneficial in preventing addi-
tional infections. Mupirocin calcium 2% oint-
ment (Bactroban) applied to both anterior
nares twice daily for 5-7 days is commonly
used for this purpose. One recent encourag-
ing study utilized a triple approach with an
oral regimen of rifampin and doxycycline,
intranasal 2% mupirocin ointment, and 2%
chlorhexidine gluconate for washing.(40) In
this study, 112 hospitalized patients who
were colonized with MRSA were randomized
to receive this decolonization therapy for
seven days or no treatment. Of those treat-
ed, 74% had negative MRSA cultures at 3
months, while only 32% of those who were
not treated were culture-negative at follow-
up. Eight months later, 54% of those who
were treated remained culture-negative. This
same study found that patients who were col-
onized with mupirocin-resistant MRSA at
baseline were more than nine times likely to
fail treatment. Although worthy of further
study, widespread utilization of this approach
within the correctional setting cannot be rec-
ommended at this time. 
Education: Inmates
All inmates should be educated about the
importance of seeking prompt evaluation and
treatment for all potentially contagious condi-
tions.  Specific educational points concerning  
MRSA include:
Education: Employees
1996, the CDC and the HICPAC jointly
issued new guidelines for routine infection
control precautions.(41) These precautions,
termed standard precautions, have replaced
universal precautions. During new employee
orientation and again during annual in-ser-
vice training, all employees should be edu-
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Wash hands regularly with soap and
water.  If hands are not visibly soiled,
alcohol-based hand cleansers are a
reasonable alternative. 
Maintain good hygiene by showering
regularly.
Do not share personal items that can
transmit infectious agents, such as
clothing, towels, bedding, razors, hair
brushes and combs, and soap.
Utilize the institutional laundry, and
have clothes washed regularly espe-
cially if they have come into contact
with wounds or wound drainage.
Keep all wounds covered with a
clean, dry bandage.
Do not assist other inmates in the
drainage or bandaging of wounds.
Leave these activities to trained med-
ical staff.
Continued on page 5
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cated concerning standard precautions that
have been specifically modified for relevance
in the correctional setting (See Standard
Precautions 101). All employees should be
made aware of their role in facilitating the
rapid evaluation of all inmates who may have
skin and other soft tissue infections. 
In addition to standard precautions, the CDC
has published transmission-based precau-
tions to be used based upon the mechanism
of transmission of specific organisms.
Transmission-based precautions fall into
three main categories: airborne, droplet, and
contact. Airborne precautions are to be used
for organisms that are transmitted via the
respiratory route by small particle aerosols,
such as Mycobacterium tuberculosis and
Varicella zoster virus. Droplet precautions
are used for organisms that are transmitted
by larger droplets either through the air for
short distances or by contaminated surfaces,
such as influenza virus.  Contact precautions
are to be used for organisms that are trans-
mitted by contact with the skin of an infected
or colonized person or with contaminated
surfaces.  Examples include most diarrheal
pathogens, lice, scabies, and MRSA.  All cor-
rectional employees should be familiar with
transmission based (contact) precautions
that are appropriate for the correctional set-
ting (See Standard Precautions 101). 
The importance of infection control measures
cannot be overemphasized, as even many
healthcare professionals neglect hand wash-
ing. In an effort to improve hand hygiene, the
use of alcohol-containing antiseptic scrubs is
increasingly being encouraged. However,
security concerns may lead to these particu-
lar disinfectants not being universally
embraced in the correctional setting.
Environmental surfaces that are used by
multiple people should be routinely deconta-
minated.
Inmates commonly wash their own clothes
using soap and tap water. This process may
remove soil and odors, but does little to kill
pathogenic organisms.  Inmates should be
educated that the only way to reliably remove
organisms that can cause disease is to use
the institutional laundry.  A laundry tempera-
ture of at least 71 degrees Celsius (160
degrees F) for a minimum of 25 minutes has
commonly been recommended to effectively
kill microorganisms.42 Lower temperature
washing at 22-50 degrees Celsius can effec-
tively reduce microorganism concentrations
when adequate amounts of chlorine bleach
are utilized.43,44 The high temperatures
achieved during drying and ironing are also
microbicidal. 
The involvement of experts in infection con-
trol and infectious diseases can be useful in
both managing individual patients and estab-
lishing protocols specific to the unique needs
of each facility. Correctional facilities experi-
encing outbreaks of MRSA should seek
assistance from their local and state health
departments. MRSA outbreaks can be
reported to CDC through state departments
of corrections and state health departments
(telephone: 800.893.0485). Preventing
MRSA infections among inmates might be an
important measure for preventing MRSA in
the community outside the correctional facili-
ty. Additional information about MRSA is
available at the CDC website
(www.cdc.gov).45
Conclusions
Infections due to MRSA have become an
increasingly common cause of morbidity and
mortality in this country. Outbreaks have
been recognized within health care settings,
long-term care facilities, and in a variety of
community settings.  Congregate living envi-
ronments such as jails and prisons have
been particularly impacted by this pathogen.
A variety of measures can be implemented
that can improve the prevention, early diag-
nosis, and treatment of disease attributable
to MRSA.  Research on best practices in jails
and prisons is urgently needed to help guide
correctional professionals in best addressing
this problematic pathogen. 
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Table 1.  Antibiotic Treatment Options for MRSA
Trimethoprim-Sulfamethoxazole
(Septra, Bactrim)
Minocycline (Minocin) and 
Doxycycline (Doryx)
Clindamycin (cleocin)
Rifampin (Rifampicin)
Vancomycin (Vancocin)
Quinupristin -Dalfopristin
(Synercid)
Linezolid (Zyvox)
Daptomycin (Cubicin)
PO, IV
PO
PO, IV
PO
IV
IV
IV, PO
IV
Skin and soft tissue infec-
tions. Not specifically FDA
approved for infections due
to MRSA.
Skin and soft tissue infec-
tions. Not specifically FDA
approved for infections due
to MRSA.
Skin and soft tissue infec-
tions, bone infections.  Not
specifically FDA approved
for infections due to MRSA.
Should not be used as a
single agent.  May be used
in combination for treat-
ment and eradication of
MRSA.
Endocarditis, bacteremia,
bone/joint infections.
Skin and soft tissue infec-
tions.
Skin and soft tissue infec-
tions, pneumonia.
Skin and soft tissue infec-
tions.
1 double strength tablet
(160 mg TMP/800 mg
SMX) po bid
100 mg po bid
300-600 mg po tid-qid
600 mg po qd
1000 mg q 12 hours
7.5 mg/kg q 8-12 hours 
600 mg q 12 hours
4 to 6 mg/kg q day 
Anemia, neutropenia, rash,
pruritus, Stevens-Johnson
syndrome. Not recom-
mended during the third
trimester of pregnancy.
Photosensitivity, rash. Not
recommended for use dur-
ing pregnancy.
Rash, Clostridium difficile
colitis 
Rash, liver inflammation.
High frequency of drug-
drug interactions.
Hypersensitivity reactions,
red man syndrome. 
Arthralgias, myalgias.
Bone marrow suppression.
Note: Not recommended
for routine oral use due to
potential for inducing resis-
tance, toxicity, and high
cost.
Myopathy.
Antibiotic Route Indications Routine Dose Major Side Effects
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Introduction
Over the past several years a number of new
antimicrobial agents have been approved by
the United States Food and Drug
Administration (FDA) for the treatment of Gram
positive infections, and additional drugs for
such organisms are likely to be developed.
Tigecycline, daptomycin, linezolid and quin-
upristin-dalfopristin are therapeutic alternatives
to vancomycin when clinical failure to this drug
occurs, in cases of infection with vancomycin
resistant organisms or following intolerable
side effects attributed to vancomycin.  Although
these newer agents provide alternative options
to treat many Gram positive infections, van-
comycin still remains the treatment of choice
for many drug-resistant Gram positive organ-
isms.  In clinical trials, these newer agents
have often been proven to be non-inferior to
(that is, not significantly worse than) van-
comycin, but these studies have rarely been
powered sufficiently to demonstrate superiority
over vancomycin.  While the new antimicro-
bials have broadened the treatment options for
a variety of difficult-to-treat infections, they are
also are associated with an increase in drug
acquisition costs and may cause significant
adverse drug effects.  Additionally, these drugs
are not resistance-proof and reduced suscepti-
bility to each has been documented.  Below,
we review the major new antimicrobials for
Gram positive infections and highlight their rel-
ative strengths and limitations.
Tigecycline
Tigecycline is a glycylcycline antibiotic derived
from the tetracyclines.  Similar to the tetracy-
clines, tigecycline is a bacteriostatic agent and
inhibits bacterial growth by binding to the 30S
ribosomal subunit.  Cross-resistance between
tigecycline and the tetracyclines is not univer-
sal due to tigecycline's ability to overcome two
key mechanisms of resistance: antibiotic efflux
and ribosomal protection.  Its spectrum of
activity includes Gram positive, Gram negative
and anaerobic organisms, including methicillin-
sensitive and -resistant Staphylococcus
species (i.e. MSSA and MRSA), vancomycin-
sensitive (VSE) and -resistant Enterococcus
species (VRE), Streptococcus species, E. coli,
Acinetobacter species, Klebsiella species,
Enterobacter species, S. maltophilia,
Citrobacter species, and Serratia. The drug
has excellent activity against anaerobic organ-
isms including Bacteroides species.
Tigecycline also has in vitro activity against
Mycobacterium species, but there are limited
clinical data to support its use for these organ-
isms.  Importantly, tigecycline does not have
anti-pseudomonal activity and has limited
activity against Proteus species and
Providencia species.
Tigecycline is only available as an injection and
is administered parenterally as a 1-hour infu-
sion.  It has an extended half-life ranging from
37 to 67 hours and undergoes hepatic metab-
olism.  Tigecycline produced high levels in tis-
sues, including the lung, skin and gastrointesti-
nal organs; however, levels do not routinely
exceed the MIC of the organism in the serum
or urine. Tigecycline also does not penetrate
into the central nervous system (CNS) and is
not eliminated through the kidneys.  Thus, tige-
cycline should not routinely be used for
catheter-related blood infections, bacteremias,
endocarditis, brain abscesses, meningitis or
urinary tract infections due to poor penetration
to these sites of infection.  Tigecycline requires
a 100 mg IV loading dose followed 50 mg IV
every 12 hours (See Table 2).  Dose reduction
is recommended for patients with moderate-to-
severe liver dysfunction. The overall incidence
of adverse events did not different between
tigecycline and the comparator agents in ran-
domized studies with the exception of nausea
and vomiting, which occurred in 20-35% of
patients.1,2 The frequency and severity of
these symptoms tend-to-be dose related and
dissipate after the first 2-3 days of therapy in
the majority of patients.  Premedication with
antiemetic agents (i.e. promethazine) 30 min-
utes prior to the tigecycline administration may
decrease the incidence of nausea and vomit-
ing.  Other side effects included headache and
pruritis.
Tigecycline is FDA-approved for the manage-
ment of complicated skin and soft tissue infec-
tions and complicated intra-abdominal infec-
tions.  A New Drug Application has been sub-
mitted to the FDA for the treatment of hospital-
acquired pneumonia and ventilator-associated
pneumonia.
Daptomycin
Daptomycin is a cyclic lipopeptide antibiotic
and the first member of the class to be FDA
approved.  Daptomycin is bactericidal, and its
mechanism of action is through the insertion of
the drug's lipophilic tail into the bacterial cell
membrane causing cell wall depolarization.
This allows for potassium efflux leading to inhi-
bition of DNA, RNA and protein synthesis - ulti-
mately resulting in cell death.  Unlike van-
comycin and beta-lactam agents such as peni-
cillins, daptomycin does not cause bacterial
cell lysis and thus, endotoxins from being
released.  This, theoretically, can be advanta-
geous as some toxins released from infected
cells can cause inflammatory reactions.  Its
spectrum of activity is limited to Gram positive
organisms, including MRSA and MSSA,
Glycopeptide-Intermediately Resistant
Staphylococcus, vancomycin-sensitive and-
resistant Enterococcus species and
Streptococcus species.  Like vancomycin and
beta-lactams, daptomycin has been shown to
have synergistic effects when used with amino-
glycosides and rifampin.  
Daptomycin is only available as an injection
and is administered parenterally as a 30-
minute infusion.  Similar to aminoglycosides
and fluorquinolones, daptomycin displays con-
centration-dependent-killing and a post-antibi-
otic effect.  Its half-life is approximately 8
hours, allowing for once-daily dosing.  Early
studies demonstrated an increase risk of rhab-
domyolysis when daptomycin was adminis-
tered twice a day. However, the risk of rhab-
domyolysis is low when administering dapto-
mycin once-daily.  Daptomycin obtains high -
aconcentrations in the serum and in most tis-
sue compartments.  It undergoes renal elimi-
nation requiring dose reductions for patients
with severe renal dysfunction.  Daptomycin
does not penetrate the cerebral spinal fluid
(CSF) and should not be used for the manage-
ment of meningitis or brain abscesses.
Additionally, daptomycin is inactivated in the
lung by surfactant and is not effective for the
treatment of pneumonia.  
The dose of daptomycin is 4-6 mg/kg IV daily
depending on the site of infection (See Table
2).  Elevated creatine phophokinase (CPK)
may occur with daptomycin therapy.  Baseline
CPK level and follow-up levels should be mon-
itored.  If elevations occur, daptomycin should
be discontinued in patients who are asympto-
matic with CPK levels 10 times the upper limit
of normal or in patients who are symptomatic
with CPK levels 5 times the upper limit of nor-
mal.
Daptomycin is FDA-approved for the manage-
ment of complicated skin and soft tissue infec-
tions and Staphylococcus bacteremias with or
without right-sided, native valve endocarditis.
Linezolid
Linezolid is the first antimicrobial agent in the
oxazolidinone class and exerts its antibacterial
effect by binding to the 50S subunit of the ribo-
some, preventing 70S formation and resulting
in inhibition of bacterial synthesis.  Its spectrum
of activity consists of Gram positive organisms,
including methicillin-sensitive and -resistant
Staphylococcus species, vancomycin-sensitive
and -resistant Enterococcus species,
Streptococcus species.
Linezolid is available in oral and injectable for-
mulations.  Due to high bioavailability, linezolid
can be converted from the intravenous formu-
lation to the oral formulation at the same dose.
Linezolid achieves high concentrations in the
lung, liver, spleen, skin and vascular system.
Linezolid concentrations 30-60% of plasma
levels have been identified in the CSF in case
reports.  Approximately 60-70% of the drug is
eliminated via the biliary system with remaining
drug elimination via the kidney.  The standard
dose is 600 mg IV or PO every 12 hours (see
Table 2).  Dose reductions are not required for
patients with renal or hepatic dysfunction.  
Long-term use of linezolid has been associat-
ed with optic neuritis, peripheral neuropathy
and bone marrow suppression. The most com-
monly reported hematologic side effect attrib-
uted to linezolid is thrombocytopenia - occur-
ring in up to 30% of recipients.  However, more
recent data has demonstrated the risk of line-
zolid-induced thrombocytopenia is similar to
vancomycin when administered for less than
14 days.3 Linezolid is a weak MOA-I type B
inhibitor and has been associated with sero-
tonin syndrome when used concomitant sero-
tonergic agents. Serotonin syndrome sec-
ondary to linezolid is uncommon and does not
preclude the use of linezolid with serotonergic
agents. However, patients should be carefully
monitored for clinical signs and symptoms of
serotonin syndrome when initiating these
agents together. 4-6
Linezolid is FDA-approved for the treatment of
vancomycin-resistant Enterococcus faecium
infections (VRE), nosocomial pneumonia,
complicated and uncomplicated skin and soft
tissue infections and community acquired
pneumonia.
Quinupristin-dalfopristin
Quinupristin-dalfopristin is a 30:70 mixture of a
streptogramin B and A. Quinupristin-dalfo-
pristin inhibits bacterial synthesis by binding to
the 50S ribosomal subunit.  When adminis-
tered individually, quinupristin and dalfopristin
exert modest antimicrobial activity and are usu-
ally bacteriostatic. When administered con-
comitantly, quinupristin and dalfopristin are
more potent and able to overcome antimicro-
bial resistance.  The spectrum of activity of this
drug is limited to Gram positive organisms,
including methicillin-sensitive and -resistant
Staphylococcus spp and Streptococcus spp.
Of note, Quinupristin-dalfpristin is only active
against Enterococcus faecium, including van-
comycin-resistant strains, and is not active
against Enterococcus faecalis.
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Quinupristin-dalfopristin is only available as an
injection and is preferably administered
through a central venous catheter as it is often
causes thrombophlebitis. The recommended
quinupristin-dalfopristin dose is 7.5 mg/kg IV
every 8 to 12 hours (See Table 2).  It under-
goes extensive hepatic metabolism and is not
renally eliminated. Quinupristin-dalfopristin
inhibits CYP450 3A4, which may result in
increased drug concentrations for agents
metabolized by this hepatic process.  Due to its
hepatic metabolism, quinupristin-dalfopristin
may cause elevations of AST and/or ALT as
well as elevations in total bilirubin.
Approximately 10% of patients will develop
severe arthralgias and myalgias during quin-
upristin-dalfopristin therapy.  Due to alternative
agents with more extensive clinical data and
more tolerable side effect profiles, quinupristin-
dalfopristin should be reserved for treatment
failures or when alternate agents cannot be
administered.  
Quinupristin-dalfopristin is FDA-approved for
the management of vancomcyin Resistant
Enterococcus faecium infections, including
bacteremia and complicated skin and soft tis-
sue infections.  
Gram positive agents in drug development
Several pharmaceutical companies have Gram
positive agents in clinical trials.  Oritavancin,
dalbavancin and televancin are members of a
new antibiotic class called the lipoglycopep-
tides.  Lipoglycopeptides possess Gram posi-
tive antibacterial activity including organisms
with decreased vancomycin susceptibilities.
Dalbavancin and televancin have received
Fast Track status from the FDA for approval
consideration and may be available by the mid-
dle of 2007 to early 2008.  Another agent which
has received Fast Track status is ceftobiprole,
a cephalosporin with broad Gram negative and
Gram positive antimicrobial activity, including
Pseudomonas and methicillin-resistant
Staphylococcus spp. Similar to other
cephalosporins, ceftobiprole is not effective
against Enterococcus spp. 
Conclusion
As Gram positive infections - including antimi-
crobial resistant strains - continue to emerge
as a major cause of community, institutional
and hospital acquired infections, development
of new agents to treat these infections is criti-
cal.  Newer agents for infections caused by
Gram positive organisms have a number of
strengths and limitations compared to older
agents such as vancomycin.  Clinicians need
to become familiar with these drugs in order to
prescribe them safely and appropriately.
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Table 2. New Agents for the Management of Gram Positive Infections
Linezolid 
(Zyvox)
Daptomycin
(Cubicin)
Tigecycline 
(Tygacil)
Quinupristin/ 
Dalfopristin 
(Synercid)
600 mg IV or PO Q12h
No dose adjustments for
renal or hepatic dysfunc-
tion
Superficial infections: 4
mg/kg IV Q24h
Severe or systemic infec-
tions: 6 mg/kg IV Q24h
Dose adjustment for renal
dysfunction (CrCl <30
including HD): 4 to 6
mg/kg Q48h 
100 mg IV Loading dose
followed 12 hours after by
50 mg IV Q12h
Dose adjustment for
severe hepatic dysfunc-
tion: 100 mg IV Loading
dose followed 12 hours
after by 25 mg IVQ12h
7.5 mg/kg IV Q8-12h
No dose adjustment is
needed for hepatic or
renal dysfunctionneeded
for hepatic or renal dys-
function
-   S. aureus 
(MSSA and MRSA)
-   Streptococcus spp
-   Enterococcus spp
(including VRE)
-   S. aureus 
(MSSA and MRSA)
-   Streptococcus spp
-   Enterococcus spp
(including VRE)
Gram Positive
-   S. aureus 
(MSSA and MRSA)
-   Streptococcus spp
-   Enterococcus spp
(including VRE)
Gram Negative
-   Acinetobacter spp
-   E. coli
-   Klebsiella spp.
-   Enterbacter spp.
-   Citrobacter spp
-   S. maltophilia
-   Serratia spp
Anaerobes
-   S. aureus
(MSSA and MRSA)
-   Streptococcus spp
-   Enterococcus faecium
(including VRE)
-   Vancomycin-resistant
Enterococcus faecium
infections
-   Nosocomial 
pneumonia
-   Complicated &
uncomplicated skin an
soft-tissue infection
-   Community-acquired
pneumonia
-   Complicated skin and
soft-tissue infection
-   Staphylococcus 
bacteremia
-   Right-sided nativ
valve endocarditis due 
to Staphylococcus
-   Complicated intra
abdominal infections
-   Complicated skin and
soft-tissue infection
-   New Drug Application  
(NDA)  submitted for  
hospital-acquired 
pneumonia
-   Vancomycin-resistant
Enterococcus faecium
infections includin
bacteremia
-   Complicated skin an
soft-tissue infection
-   Bone marrow suppression, especially     
thrombocytopenia
- Prolonged use (>14 days)
- Overdoses
-   GI intolerance
-   Rare events include serotonin syn 
drome when administered with con 
comitant serotonergic agents, optic 
neuritis and peripheral neuropathy
-   Elevations in CK that may cause rha
domyolysis 
-   Inactivated by surfactant and should 
not be used for treatment of 
pneumonia
-   Nausea and vomiting (15-25%); 
usually diminishes after 2-3 days 
of therapy
-   Does not concentrate in serum or  
urine; should not be routinely used for  
bacteremias and/or urinary tract
infections
-   Arthralgias and/or myalgias
-   Thrombophlebitis
-   Inflammation and/or pain at 
infusion site
-   Drug interactions may occur as inhibits 
CYP3A4, a major metabolic pathway  
for certain medications
Agent Adult Dose & Frequency In Vitro Activity
FDA-Approved
Indications
Side Effect
Profile/Comments
1 Babinchak T, Ellis-Grosse E, Dartios N, et al. The
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Pooled Clinical Trial Data.  Clinical Infectious Diseases
2005;41:S354-67.
2 Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The
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Double-Blind Phase 3 Comparison Studies with
Vancomycin-Aztreonam.  Clinical Infectious Diseases
2005;41:S341-53.
3.Rao N, Ziran BH, Wagener MM, Santa ER, Yu VL.
Similar hematologic effects of long-term linezolid and
vancomycin therapy in a prospective observational
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4.Huang V, Gortney JS. Risk of serotonin syndrome
with concomitant administration of linezolid and sero-
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Dec;26(12):1784-93.
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Proposed Standard Precautions For All Patient Care Activities Within the Correctional Setting 
Hands should be washed routinely, regardless of whether gloves were worn:
-   after touching body fluids or contaminated items
-   before eating
-   after using the restroom
-   when hands are visibly dirty
-   before moving from one patient to another
-   when moving from a contaminated to a clean site on the same patient
HCWs should avoid wearing artificial fingernails while providing health care.
HCWs should limit the wearing of rings while providing health care.
Gloves should be worn if contact with blood or another potentially contagious body
fluid is likely.  Sweat is not a potentially infectious fluid.  
Gloves do not replace the need for hand washing.
Gloves are intended for single use.
Goggles and face shields are not a part of standard precautions. Consider the use of
goggles or face shields if involved in a procedure that may lead to splashing of body
fluids.
A gown should be used if contact with blood, potentially contagious body fluids, or a
contaminated environmental surface is likely.  
Always have a puncture resistant leak proof container at the site where a sharp
instrument is used. 
If necessary to use a sharp instrument in a cell, take along a portable sharps con-
tainer for immediate disposal of used sharp instrument. 
Immediately dispose of all used sharps in a sharps container.  
Do not transport used sharps except in an approved sharps container Do not pass
used sharps from person to person. 
Do not bend, break, or recap sharps prior to disposal.
Avoid overcrowding.
Inmates should have access to:
-   soap and water
-   showers
Inmates should be provided an ample supply of clean laundry.
Inmates who have conditions that predispose to soiling clothing with blood/body flu-
ids should be provided additional laundry access.
Inmates should be discouraged from washing their own clothing. Soap and water
can remove dirt and odors, but cannot disinfect clothing.
Laundry must either reach a temperature of 160 degrees F for a minimum of twenty-
five minutes or be done with sufficient bleach to allow for cold disinfection.
Clothes dryers also serve as disinfecting agents and pediculicides.
Clothing that has been soiled with blood, purulent matter, and other potentially con-
tagious body fluids should be bagged by the user and then placed in a leak proof
bag prior to transport to the laundry.
Laundry workers should utilize appropriate PPE.
All inmate housing areas should be cleaned on a regular schedule utilizing approved
disinfectants.
Common areas such as booking and bus screen areas, showers, toilets, day rooms,
gymnasiums, weight equipment, and clinic waiting rooms should be cleaned fre-
quently.
Perform transportation in a hygienic manner while adhering to all listed standard pre-
cautions.
Attempts should be made to remove barriers to access to care for those who have
potentially contagious skin and soft tissue infections.
Area Comments Recommendations
Hand hygiene: 
Hand washing
Hand hygiene:
Artificial
fingernails
Hand hygiene:
Rings
Personal protective
equipment: Gloves
Personal protective
equipment: Goggles
and face shield
Personal protective
equipment: Gowns
Sharps
Housing of inmate
patients
Patient hygiene
Laundry
Housekeeping
Transportation
Access to 
medical care
Most infections are transmitted from
person to person, often on the hands
of health care workers.  Routine use
of soap and water is the most effec-
tive way to remove dirt and potential-
ly pathogenic organisms. Alcohol-
based hand washes are also very
effective, and may be useful adjuncts
to hand washing with soap and
water.
Potential safety and security issues
must be addressed prior to the intro-
duction of alcohol- based hand wash-
es.
The wearing of artificial fingernails by
HCWs has been associated with the
transmission of resistant organisms.
The wearing of rings by HCWs has
been associated with an increased
risk for transmission of bacteria to
patients.
Disposable gown
Overcrowding can facilitate the trans-
mission of many contagious illness-
es.
Poor hygiene can facilitate the trans-
mission of may contagious illnesses.
Inadequate supply of clean clothing
and linen can facilitate the transmis-
sion of many contagious illnesses.
Environmental surfaces can be a
source of transmission of contagious
organisms.
Transportation vehicles can be a
source of transmission for a variety
of contagious illnesses.
Barriers to health care have been
found to be a risk factor for MSRA
infection.
Proposed Transmission Based (Contact) Precautions for Patients with Confirmed/Suspected MRSA in the
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Bureau of Prisons Clinical Practice Guidelines for the Management of
MRSA. August 2005. 
www.bop.gov/news/PDFs/mrsa.pdf
County of Los Angeles, Department of Health Services, Public Health.
Guidelines for Reducing the Spread of Staph/CAMRSA in Non-Healthcare
Settings.
www.lapublichealth.org/acd/docs/MRSA/MRSA_Guideline_12_20_04.pdf
King County Public Health, Seattle, WA. Interim Guidelines for Evaluation
and Management of Community- Associated MRSA Infections in
Outpatient Settings. September 2004. 
www.metrokc.gov/health/providers/epidemiology/MRSA-guidelines.pdf
CDC's website on Healthcare-Associated MRSA (HA-MRSA)
http://www.cdc.gov/ncidod/dhqp/ar_mrsa.html
CDC's website for Providers on CA-MRSA Information.
www.cdc.gov/ncidod/dhqp/ar_mrsa_ca.html
CDC. Methicillin-Resistant Staphylococcus aureus Infections in
Correctional Facilities- Georgia, California, and Texas, 2001-2003. MMWR.
October 17, 2003;52(41):992-96. 
www.cdc.gov/mmwr/preview/mmwrhtml/mm5241a4.htm
CDC. Methicillin-Resistant Staphylococcus aureus Skin or Soft Tissue
Infections in a State Prison --- Mississippi, 2000. MMWR. October 26,
2001;50(42):919-22.
www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a2.htm
Slides from the NCCHC Pre-conference Seminar
Infectious Diseases in Corrections: An Expert Panel
October 28, 2006
http://www.idcronline.org/archives.html
Department of Health and Human Services 
2006 Adult and Adolescent Antiretroviral Treatment Guidelines
http://www.aidsinfo.nih.gov/guidelines/
International AIDS Society-USA Panel 
2006 Recommendations of the Treatment for Adult HIV Infection
http://jama.ama-assn.org/cgi/content/full/296/7/827
CDC's Revised Recommendations for HIV Testing of Adults, Adolescents,
and Pregnant Women in Health-Care Settings
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm
American Academy of HIV Medicine
http://www.aahivm.org/
RESOURCES
As per standard precautions.
Gloves should be worn whenever entering the room of a patient who is on contact
precautions for MRSA. 
Gloves should be removed and discarded prior to leaving the patient's room.
Eye protection and face shields are generally not a part of standard precautions to
prevent the transmission of MRSA. These items should only be used during proce-
dures that are likely to cause splashing of body fluids into the eyes or mouth.
A gown should be worn whenever entering the room of a patient who is on contact
precautions for MRSA. 
As per standard precautions.
Avoid sharing patient care equipment that has been used on patients who are on
contact precautions. If sharing is unavoidable, clean/disinfect the equipment before
re-use. 
In addition to the measures noted in standard precautions:
-   If available, utilize single cell housing for inmates who have draining skin 
lesions presumed or confirmed to be secondary to MRSA.
-   If single cell housing is not available, cohort those who have draining skin 
lesions in a dedicated dormitory setting.
-   Inmates who have draining skin lesions and who are unable or unwilling to 
maintain personal hygiene should be placed in an infirmary setting.
As per standard precautions.
In addition to the details in standard precautions, consideration should be given to
the establishment of dedicated wound care clinics and/or wound care teams that
attend to inmates in their cells/dorms.
As per standard precautions.
As per standard precautions. 
In addition, implement frequent and terminal  cleaning/disinfection of clinical areas
and housing of those who are infected with MRSA. Surfaces should be cleaned with
either a 1:100 solution of diluted bleach or an EPA-registered hospital disinfectant. 
In addition to the details in standard precautions:
-   Limit inmate movement to that which is medically/legally necessary. 
-   Utilize dressings that entirely cover any skin lesions and contain any drainage 
precautions.
-   Use disposable or washable restraints.
-   Clean transportation vehicle after transport of the infected person.
In addition to the details in standard precautions, those who have draining wounds
should be excluded from:
-   Communal/contact athletic activities
-   Culinary employment
-   School attendance
-   Chapel
-   Other non-essential group activities
Area Comments Recommendations
Hand hygiene
Personal protective
equipment
Personal protective
equipment
Personal protective
equipment
Sharps
Patient care 
equipment
Housing of inmate
patients
Patient hygiene
Access to medical
care
Laundry
Housekeeping/
sanitation
Transportation
Inmate activities
As per standard precautions.
Gloves
Eye protection, face shields
Disposable gown
Sharps injuries are not a common
mechanism for the transmission of
MRSA.
Patient care equipment (stetho-
scopes, blood pressure cuffs, oto-
scopes, etc.) can become contami-
nated and lead to transmission of
pathogenic organisms. 
Overcrowding and contact with a per-
son who is infected or colonized with
MRSA have been found to be risk
factors for MRSA infection. 
Poor hygiene has been found to be a
risk factor for MRSA infection.
Barriers to health care have been
shown to be risk factors for MRSA
infection.
Inadequate supply of clean clothing
and linen has been found to be a risk
factor for MRSA infection.
Environmental surfaces can be a
source of MRSA transmission.
A variety of activities have been
shown to lead to person-to-person
transmission of MRSA.
Academic and Health Policy
Conference on Correctional Health
Sponsored by the University of
Massachusetts Medical School 
and UMass Correctional Health
Boston, MA
March 29-30, 2007
Visit:www.umassmed.edu/commedin-
terior.aspx?id=33110
A System-wide Approach to
Managing Chronically Ill Patients in
Correctional Health Care
Quincy, MA
March 31, 2007
Sponsored by the National
Commission on Correctional Health
Care and the Academy of Correctional
Health Professionals 
Visit: www.correctionalhealth.org/edu-
cation/seminar_quincy.html
16th Annual HIV Conference of the 
Florida/Caribbean AIDS Education
and Training Center
Orlando, FL
March 30-31, 2007
Visit:www.faetc.org/Conference/
Occupational & Non-Occupational
Post Exposure Prophylaxis
Albany Medical College 
Accredited Satellite Videoconference
& Webstream
April 11, 2007
12:30 - 2:30 p.m. (E.T.)
Visit:www.amc.edu/hivconference
Email: ybarraj@mail.amc.edu
Phone: 518.262.4674
Updates in Correctional Health Care
Orlando, FL
May 5-8, 2007
Visit:www.ncchc.org/education
/index.html
Hepatitis in Corrections 
Sponsored by the University of Texas
Medical Branch and the 
Texas/Oklahoma AIDS Education and
Training Center
May 18, 2007
Moody Gardens Convention Center
Galveston, TX
Email: Victoria Korschgen at 
vikorsch@utmb.edu
CME and CNE Credits Available 
The 34th Annual International
Conference on Global Health
May 29 - June 1, 2007
Washington, D.C.
Visit:www.globalhealth.org/2007_con-
ference/
Correctional Mental Health Seminar
Las Vegas, NV
July 15-16, 2007
Visit:
www.ncchc.org/education/MH2007/las
vegas.html
IAS 2007: 4th IAS Conference on
HIV Pathogenesis, Treatment and
Prevention
Sydney, Australia
July 22-27, 2007
Visit:www.ias2007.org/start.aspx
SAVE THE
DATES
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Personal Hygiene and Methicillin Resistant
Staphylococcus Aureus (MRSA) Infection
Investigators from the Missouri Department of
Health and Senior Services conducted a case-con-
trol study to examine the risk factors for MRSA
infection during a 2002-2003 outbreak in a Missouri
women's correctional facility. The study, which
largely focused on personal hygiene factors, found
that MRSA infection was significantly associated
with low composite hygiene scores among the pris-
oners, after controlling for socio-demographic and
other risk factors.  The composite hygiene score
was created on the basis of three individual hygiene
practices: the frequency of hand washing per day,
showers per week, and number of personal items
shared with other inmates.  Of the 55 confirmed
MRSA cases, thirty were still available for interview
at the time of investigation and 80 inmates were
randomly selected as controls. Transmission
among inmates appeared to be responsible for the
outbreak as pulsed-field gel electrophoresis demon-
strated that MRSA isolates were indistinguishable.  
Based on these results, the authors conclude that a
prison environment can easily become contaminat-
ed by MRSA, especially due to the inmates' improp-
er care of infected skin lesions, poor personal
hygiene, and close contact within a confined space.
The study was limited by the recall bias of partici-
pants and the findings may not be applicable to
other populations as all subjects were adult women.
However, the authors assert that targeted education
about MRSA infection, especially the importance of
proper personal hygiene, should be an integral part
of efforts to eliminate and prevent MRSA infections
in prison settings, where inherent restrictions com-
plicate the implementation of certain control mea-
sures.
Personal Hygiene and Methicillin Resistant
Staphylococcus Aureus Infection.  Turabelidze, G. et
al.  Emerging Infectious Diseases. 2006;12(3):422-
27. 
Meticillin-Resistant Staphylococcus Aureus
Among U.S. Prisoners and Military Personnel:
Review and Recommendations for Future
Studies
In this study, published in The Lancet, investigators
reviewed published research examining the preva-
lence and transmission dynamics of MRSA infection
in two high-risk groups: prisoners and military enlis-
tees.  Significant risk factors included prison occu-
pation, gender, comorbidities, prior skin infection,
and previous antibiotic use.  Although several stud-
ies suggest that crowded living and work environ-
ments, demanding physical activity, and poor
hygiene are important risk factors, the authors
found few studies that directly tested the epidemio-
logical association with these suggested risk fac-
tors.  Given the inherent barriers to infection control
measures in these populations, the authors are
concerned by the overall lack of research in these
areas.  Additionally, most of the identified studies
were retrospective in design, with only one study
utilizing prospective surveillance for MRSA colo-
nization.  Thus, the authors propose that future
research seek to quantify the prevalence of MRSA
infection among the entire population in prisons and
military settings, rather than only those individuals
affected by outbreaks.  A more thorough examina-
tion of MRSA acquisition and transmission patterns
in these settings might elucidate improved preven-
tive strategies in other crowded and closed settings.  
Meticillin-Resistant Staphylococcus Aureus Among
U.S. Prisoners and Military Personnel: Review and
Recommendations for Future Studies.  Allelo, A.E.
et al.  The Lancet.  2006;6:335-41. 
Feasibility and Acceptability of Rapid HIV
Testing in Jail
In a study of 100 randomly selected male inmates
within the Rhode Island Department of Corrections
Jail (RIDOC) - the central facility serving the entire
state of Rhode Island - researchers found that there
was high acceptance of rapid HIV testing (95/100).
Participants in the study completed a questionnaire
regarding risk-behavior, incarceration history, HIV-
testing history, and attitudes towards testing.  Each
prisoner then received individualized HIV risk
reduction counseling and the option of rapid HIV
testing via the OraQuick Rapid HIV test (a blood-
based test that returns results in 20-30 minutes).
Almost all participants agreed that jail is a good
place to perform HIV screening (96/100) and most
supported partner notification by the state (83/100).  
The findings of this study are significant, the authors
suggest, because rapid testing, unlike the more tra-
ditional screening methods, allows for the immedi-
ate delivery of results and post-test prevention
counseling.  In this study, all participants received
rapid test results and individualized risk reduction
counseling prior to release.  Despite the improved
delivery of final negative results, the obstacle of pro-
viding confirmatory results for those subjects with
rapid test preliminary positives remains.  The one
preliminary positive participant in the study was
released from the facility prior to receiving his con-
firmatory test result.  In assessing the limitations of
the study, the investigators note the small size of
the study and the relative comfort of RIDOC
inmates with HIV testing in the corrections setting.
Nonetheless, the authors highlight the feasibility
and overall high acceptance of rapid HIV testing
and suggest that further studies are needed to
incorporate rapid testing into jail HIV-screening pro-
grams.
Feasibility and Acceptability of Rapid HIV Testing in
Jail.  Beckwith, C.G. et al.  AIDS Patient Care and
STDs.  2007;21(1):41-47. 
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NEWS AND LITERATURE REVIEWS
Go to www.AAHIVM.org to learn about mem-
bership, continuing education and the new
partnership with IDCR
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SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for continuing
Medical Education through the joint sponsorship of Medical Education Collaborative, Inc. (MEC) and IDCR.  MEC is accredited by the ACCME to
provide continuing medical education for physicians. 
Medical Education Collaborative designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™.  Physicians should only
claim credit commensurate with the extent of their participation in the activity.  Statements of credit will be mailed within 6 to 8 weeks following the
program. 
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1. True or false. Clinicians who examine MRSA infected patients while 
wearing gloves but not gowns do not frequently acquire MRSA on 
their clothing and later transfer MRSA to their hands.
TRUE or FALSE?
2.  Which of the following should never be used as a single agent for 
the treatment of MRSA due to rapidly evolving resistance:
A. trimethoprim-sulfamethoxazole 
B. rifampin
C. clindamycin, 
D. tetracyclines minocycline
E. doxycycline
3. True or False. Unless a d-zone test has demonstrated susceptibility 
to clindamycin, this agent should not be used for SA that is 
erythromycin resistant. 
TRUE or FALSE?
4. Which of the following are part of the 2003  Society for Health Care 
Epidemiology of America (SHEA) guidelines for preventing the 
nosocomial transmission of MRSA within hospitals?
A. Limitations on antibiotic use to decrease the likelihood of 
antibiotic resistance 
B. Actively screening all at-risk patients at the time of admission 
for infection or colonization with MRSA
C. Screening for MRSA carriage
D. Use of contact precautions for all those found to be colonized 
or infected with MRSA
E. A, B, and D ONLY
5. Which of the following is NOT a part of inmate education as part of 
the routine eradication of MRSA from correctional facilities?
A. Have clothes washed regularly by the institutional 
laundry service 
B. Basic skills in the drainage or bandaging of a wound 
C Do not share personal items that can transmit infectious 
agents, such as clothing, towels, bedding, razors, hair brushes 
and combs, and soap
D. Maintain good hygiene by showering regularly
In order to receive credit, participants must score at least a 70% on the post test and submit it along with the credit 
application and evaluation form to the address/fax number indicated.  Statements of credit will be mailed within 6-8 weeks
following the program.
Please print clearly as illegible applications will result in a delay.
Name: _________________________________________________  Profession: __________________________________
License #: ___________________________________  State of License: __________________________________________
Address: ____________________________________________________________________________________________
City: ________________________ State: ________ Zip: ________________________ Telephone: ___________________
Please check which credit you are requesting  ___ ACCME   or    ___ Non Physicians
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
I certify that I participated in IDCR monograph - March 2007 Issue     
Please fill in the number of actual hours that you attended this activity.
Date of participation: ______________________  
Number of Hours (max. 1): ___________________
Signature: _________________________________________________
Please Submit Completed Application to:
Medical Education Collaborative
651 Corporate Circle, Suite 104, Golden CO 80401
Phone: 303-420-3252 FAX: 303-420-3259
For questions regarding the accreditation of this activity, please call
303-420-3252
Instructions:
• Applications for credit will be accepted until 
March 31, 2008.
• Late applications will not be accepted.
• Please anticipate 6-8 weeks to recieve your certificate.
Objectives:
The learner will be able to describe the recommended testing and treatment regimes for MRSA and other gram-positive infections. 
The learner will be will become familiar with the transmission based precautions specifically designated for both health care workers and inmates
as part of the eradication of MRSA in correctional facilities. 
The learner will be able to describe the 2003 Society for Health Care Epidemiology of America (SHEA) guidelines for preventing the
nosocomial transmission of MRSA.
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COURSE EVALUATION
I. Please evaluate this educational activity by checking the appropriate box:
Activity Evaluation
Faculty
Content
How well did this activity avoid com-
mercial bias and present content that
was fair and balanced?
What is the likelihood you will
change the way you practice based
on what you learned in this activity?
Overall, how would you rate 
this activity?
Excellent Very Good Good Fair Poor
II. Course Objectives 
Were the following overall course objectives met?  At the conclusion of this presentation, are you able to:
• The learner will be able to describe the recommended testing and treatment regimes for MRSA and other YES NO SOMEWHAT
gram-positive infections. 
•  The learner will be will become familiar with the transmission based precautions specifically designated for
both health care workers and inmates as part of the eradication of MRSA in correctional facilities. YES NO SOMEWHAT
•  The learner will be able to describe the 2003 Society for Health Care Epidemiology of America (SHEA) YES NO SOMEWHAT
guidelines for preventing the nosocomial transmission of MRSA
III. Additional Questions
a. Suggested topics and/or speakers you would like for future activities.
b.  Additional Comments 
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